Las Vegas, USA, July 05, 2022 (GLOBE NEWSWIRE) — The Global Liquid Biopsy in Cancer Diagnostics Market to Surpass USD 19 Billion by 2027 | DelveInsight
The liquid biopsy in cancer diagnostics market is expected to grow due to the rise in the burden of various cancers across the globe. Moreover, a growing preference for minimally invasive procedures among the population is also a factor contributing to the growth of liquid biopsy in the cancer diagnostics market.
DelveInsight’s Liquid Biopsy in Cancer Diagnostics Market Insights report provides the current and forecast market, forthcoming device innovation, individual leading companies’ market shares, challenges, liquid biopsy in cancer diagnostics market drivers, barriers, and trends, and key liquid biopsies companies in the market.
Key Takeaways from the Liquid Biopsy in Cancer Diagnostics Market Report
- As per DelveInsight estimates, North America is anticipated to dominate the global liquid biopsy in cancer diagnostics market during the forecast period.
- The leading liquid biopsy in cancer diagnostics companies such as Myriad Genetics Inc, Exact Sciences Corporation, Biocartis, Sysmex Corporation, Thermo Fisher Scientific Inc, Biocept Inc, Agilent Technologies Inc, MDx Health, Neogenomics Laboratories, F. Hoffman La Roche Ltd, Guardant Health,Bio-Techne, Illumina Inc, QIAGEN, Lucence Health Inc, Personal Gemone Diagnostics Inc, SAGA Diagnostics, Agena Bioscience Inc, The Menarini Group, MiRXES Pte Ltd.,…
